Advertisement
Screener

ORGANOGENESIS HOLDINGS INC. (ORGO) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

ORGANOGENESIS HOLDINGS INC. Capital Expenditures

ORGANOGENESIS HOLDINGS INC. (ORGO) reported Capital Expenditures of $4.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06

  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.10M, a 69.76% decline year-over-year.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $3.15M, a 13.24% decline year-over-year.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $4.65M, a 38.41% increase year-over-year.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $2.23M, a 13.00% decline year-over-year.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for fiscal 2025 was $14.15M, a 41.06% increase from fiscal 2024.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for fiscal 2024 was $10.03M, a 58.82% decline from fiscal 2023.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for fiscal 2023 was $24.36M, a 28.13% decline from fiscal 2022.
  • ORGANOGENESIS HOLDINGS INC. payments to acquire property, plant, and equipment for fiscal 2022 was $33.90M, a 8.58% increase from fiscal 2021.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 12 monthPayments to Acquire Property, Plant, and Equipment 12 month as first filed
2026-06-30$1.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$4.25M
10-Q · filed 2026-08-06
$8.90M
derived: sum of 3 quarters · filed 2026-08-06
$11.13M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$3.15M
10-Q · filed 2026-05-07
$7.80M
derived: sum of 2 quarters · filed 2026-05-07
$10.03M
derived: sum of 3 quarters · filed 2026-05-07
$13.67M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$4.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$6.89M
derived: sum of 2 quarters · filed 2026-02-26
$10.53M
derived: sum of 3 quarters · filed 2026-08-06
$14.15M
10-K · filed 2026-02-26
2025-09-30$2.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$5.87M
derived: sum of 2 quarters · filed 2026-08-06
$9.50M
10-Q · filed 2025-11-06
$12.86M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$3.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$7.26M
10-Q · filed 2026-08-06
$10.63M
derived: sum of 3 quarters · filed 2026-08-06
$13.19M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$3.63M
10-Q · filed 2026-05-07
$6.99M
derived: sum of 2 quarters · filed 2026-05-07
$9.56M
derived: sum of 3 quarters · filed 2026-05-07
$11.44M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$3.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$5.93M
derived: sum of 2 quarters · filed 2026-02-26
$7.81M
derived: sum of 3 quarters · filed 2026-02-26
$10.03M
10-K · filed 2026-02-26
2024-09-30$2.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$4.45M
derived: sum of 2 quarters · filed 2025-11-06
$6.67M
10-Q · filed 2025-11-06
$9.99M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$4.10M
10-Q · filed 2025-08-07
$7.43M
derived: sum of 3 quarters · filed 2026-02-26
$13.40M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$2.22M
10-Q · filed 2025-05-08
$5.55M
derived: sum of 2 quarters · filed 2026-02-26
$11.53M
derived: sum of 3 quarters · filed 2026-02-26
$19.02M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$3.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$9.30M
derived: sum of 2 quarters · filed 2026-02-26
$16.80M
derived: sum of 3 quarters · filed 2026-02-26
$24.36M
10-K · filed 2026-02-26
2023-09-30$5.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$13.48M
derived: sum of 2 quarters · filed 2024-11-12
$21.04M
10-Q · filed 2024-11-12
$31.70M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$7.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$15.06M
10-Q · filed 2024-08-08
$25.72M
derived: sum of 3 quarters · filed 2025-02-27
$36.12M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$7.56M
10-Q · filed 2024-05-09
$18.22M
derived: sum of 2 quarters · filed 2025-02-27
$28.62M
derived: sum of 3 quarters · filed 2025-02-27
$34.79M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$10.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$21.06M
derived: sum of 2 quarters · filed 2025-02-27
$27.23M
derived: sum of 3 quarters · filed 2025-02-27
$33.90M
10-K · filed 2025-02-27
2022-09-30$10.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$16.57M
derived: sum of 2 quarters · filed 2023-11-09
$23.24M
10-Q · filed 2023-11-09
$28.47M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$6.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$12.84M
10-Q · filed 2023-08-09
$18.07M
derived: sum of 3 quarters · filed 2024-02-29
$34.77M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$6.67M
10-Q · filed 2023-05-10
$11.90M
derived: sum of 2 quarters · filed 2024-02-29
$28.60M
derived: sum of 3 quarters · filed 2024-02-29
$32.94M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$5.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$21.93M
derived: sum of 2 quarters · filed 2024-02-29
$26.26M
derived: sum of 3 quarters · filed 2024-02-29
$31.22M
10-K · filed 2024-02-29
2021-09-30$16.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$21.04M
derived: sum of 2 quarters · filed 2022-11-09
$25.99M
10-Q · filed 2022-11-09
$31.41M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$4.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$9.29M
10-Q · filed 2022-08-09
$14.71M
derived: sum of 3 quarters · filed 2023-03-01
$20.56M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$4.96M
10-Q · filed 2022-05-10
$10.38M
derived: sum of 2 quarters · filed 2023-03-01
$16.22M
derived: sum of 3 quarters · filed 2023-03-01
$18.39M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$5.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$11.27M
derived: sum of 2 quarters · filed 2023-03-01
$13.44M
derived: sum of 3 quarters · filed 2023-03-01
$17.68M
10-K · filed 2023-03-01
$21.14M
10-K · filed 2021-03-16
2020-09-30$5.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$8.02M
derived: sum of 2 quarters · filed 2021-11-09
$12.26M
10-Q · filed 2021-11-09
$15.72M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$2.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$6.41M
10-Q · filed 2021-08-09
$9.87M
derived: sum of 3 quarters · filed 2022-03-01
$11.14M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$4.24M
10-Q · filed 2021-05-11
$7.70M
derived: sum of 2 quarters · filed 2022-03-01
$8.98M
derived: sum of 3 quarters · filed 2022-03-01
$9.91M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$3.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$4.73M
derived: sum of 2 quarters · filed 2022-03-01
$5.67M
derived: sum of 3 quarters · filed 2022-03-01
$5.98M
10-K · filed 2022-03-01
2019-09-30$1.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$2.21M
derived: sum of 2 quarters · filed 2020-11-09
$2.53M
10-Q · filed 2020-11-09
$2.89M
derived: sum of 4 quarters · filed 2021-03-16
2019-06-30$934.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$1.25M
10-Q · filed 2020-08-10
$1.61M
derived: sum of 3 quarters · filed 2021-03-16
$2.55M
derived: sum of 4 quarters · filed 2021-03-16
2019-03-31$317.00K
10-Q · filed 2020-05-11
$679.00K
derived: sum of 2 quarters · filed 2021-03-16
$1.62M
derived: sum of 3 quarters · filed 2021-03-16
$2.11M
derived: sum of 4 quarters · filed 2021-03-16
2018-12-31$362.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$1.30M
derived: sum of 2 quarters · filed 2021-03-16
$1.79M
derived: sum of 3 quarters · filed 2021-03-16
$1.86M
10-K · filed 2021-03-16
2018-09-30$938.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$1.43M
derived: sum of 2 quarters · filed 2019-11-12
$1.50M
10-Q · filed 2019-11-12
2018-06-30$492.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$557.00K
10-Q · filed 2019-08-09
2018-03-31$65.00K
10-Q · filed 2019-05-10
2017-12-31$2.43M
10-K · filed 2020-03-09
2016-12-31$1.36M
10-K · filed 2019-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50